Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$37.86M, compared with -$45.62M a year earlier. Trailing-twelve-month operating income was -$145.04M.
Context
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 9 analysts of -$131.3M (+14.1%) for the fiscal year ending Dec 2026, a slowdown from the +20.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$37.86M-1.2% QoQ
- Last fiscal yearDec 2025
- -$152.81M+20.1% YoY
- LTMMar 2026
- -$145.04M+31.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.0% | — | — |
| 1 year | +20.1% | +14.1% | -6.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (152.81M) USD
- Year-over-year change
- +20.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (152.81M) | +20.1% |
| FY2024 | 2024-12-31 | (191.19M) | +36.2% |
| FY2023 | 2023-12-31 | (299.51M) | -31.8% |
| FY2022 | 2022-12-31 | (227.29M) | -5.0% |
| FY2021 | 2021-12-31 | (216.54M) | — |
Operating Income vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 operating income of -$145.04M is the lowest of the 11 companies compared; the peer median is -$77.41M.
- Its year-over-year change of +31.6% is the 6th highest of 11, against a peer median of +31.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$36.08M | -65.8% | — | — | |
| LTM Mar 2026 | -$39.11M | +11.3% | — | 86.8% | |
| LTM Mar 2026 | -$52.66M | +29.7% | — | 5266.4% | |
| LTM Mar 2026 | -$54.04M | +32.3% | — | — | |
| LTM Mar 2026 | -$63.66M | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$91.17M | +33.2% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$92.07M | -22.8% | — | — |
| LTM Mar 2026 | -$115.08M | +54.0% | — | 115.5% | |
| LTM Mar 2026 | -$119.21M | +49.3% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$122.7M | -94.3% | — | — |
| LTM Mar 2026 | -$145.04M | +31.6% | — | — | |
| Peer median (excluding ZNTL) | -$77.41M | +31.0% | — | 101.2% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 67.43M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 67.43M | 0 |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 175.6M | 172.73M | 235.16M | 167.77M | 107.3M |
| Selling, General & Admin | 40.94M | 54.55M | 59.4M | 87.12M | 37.72M |
| Operating Expenses | 216.54M | 227.29M | 299.51M | 258.62M | 152.81M |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| EBITDA | (207.2M) | (233.58M) | (247.6M) | (186.17M) | (144.27M) |
| EBITDA Margin | — | — | — | -276.1% | — |
| Operating Income | (216.54M) | (227.29M) | (299.51M) | (191.19M) | (152.81M) |
| Operating Margin | — | — | — | -283.6% | — |
| Interest Income | 0 | 2.26K | 0 | 0 | 0 |
| Interest Expense | 0 | 2.58M | 0 | 0 | 0 |
| Other Income / Expenses | 50.15M | (10.3M) | 6.6M | 25.5M | 16.19M |
| Income Before Tax | (166.39M) | (237.58M) | (292.91M) | (165.69M) | (136.62M) |
| Pre-Tax Margin | — | — | — | -245.7% | — |
| Income Tax Expense | (297K) | (469K) | (601K) | 177K | 442K |
| Net Income | (158.73M) | (236.81M) | (292.19M) | (165.84M) | (137.06M) |
| Net Margin | — | — | — | -246.0% | — |
| EPS (Basic) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| EPS (Diluted) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| Weighted Avg Shares | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
| Weighted Avg Shares (Diluted) | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.